1. BCLC strategy for prognosis prediction and treatment recommendation: The 2022 update;Reig;J Hepatol,2022
2. EMERALD-1: A phase 3, randomized, placebo-controlled study of transarterial chemoembolization combined with durvalumab with or without bevacizumab in participants with unresectable hepatocellular carcinoma eligible for embolization;Lencioni;J Clin Oncol,2024
3. Vogel A, Grant RC, Meyer T, Sapisochin G, O’Kane GM, Saborowski A. Adjuvant and neoadjuvant therapies for hepatocellular carcinoma. Hepatology, in press.
4. Pathologic response to pretransplant locoregional therapy is predictive of patient outcome after liver transplantation for hepatocellular carcinoma: analysis from the US Multicenter HCC Transplant Consortium;Dinorcia;Ann Surg,2020
5. Transplant oncology in primary and metastatic liver tumors: principles, evidence, and opportunities;Sapisochin;Ann Surg,2021